Abstract PS4-03-07: Association of clinical BRCA testing with multigene assay results

Abstract Purpose BRCA mutations significantly increase the lifetime risk of breast cancer. While they are strongly associated with triple-negative breast cancer, they are also found in hormone receptor-positive, HER2-negative subtypes, in which multigene assays are commonly used for risk stratification and treatment decision-making. However, the relationship between BRCA status and multigene assay outcomes remains unclear, particularly in Asian populations. This study investigates the association between clinical indications for BRCA testing and multigene assay results in Korean breast cancer patients. Methods This multicenter study included 2,542 patients with hormone receptor-positive, HER2-negative breast cancer who underwent multigene testing between 2013 and 2024. BRCA testing was performed in patients aged under 40 years, those with bilateral breast cancer, or those with a personal or family history of breast or ovarian cancer within third-degree relatives. Multi-gene assays included Oncotype DX, MammaPrint, EndoPredict, and OncoFREE, and each result was classified into high-risk or low-risk groups based on each test-specific criteria. Statistical analyses were performed using chi-square tests and logistic regression in SPSS. Results Patients were categorized as BRCA-tested group (n=798) or non-tested group (n = 1,596). In the BRCA-tested group, 19.5% were classified as high risk and 80.5% as low risk by multigene assay. pTstage, pNstage, histologic grade, progesterone receptor status, and Ki-67 level was independently associated with high risk and multigene assay result. BRCA mutation was identified in 44 patients (7 BRCA1 mutation, 37 BRCA2 mutation). BRCA mutation was independently associated with high-risk classification on multigene assay (OR 3.554, 95% CI 1.767-7.151, p < 0.001). In subgroup analysis of BRCA mutation group, among 30 patients with a family history, 20 (66.7%) were classified as high risk. Multivariate analysis also confirmed that familial history of breast or ovarian cancer was independently associated with high-risk in BRCA-mutation patients. (OR 9.752, 95% CI 1.449-65.651, p